BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Reference Citation Analysis]
2 Chen W, Gao C, Shen J, Yao L, Liang X, Chen Z. The expression and prognostic value of REXO4 in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1704-17. [PMID: 34532121 DOI: 10.21037/jgo-21-98] [Reference Citation Analysis]
3 Wang J, Wei B, Thakur K, Wang CY, Li KX, Wei ZJ. Transcriptome Analysis Reveals the Anti-cancerous Mechanism of Licochalcone A on Human Hepatoma Cell HepG2. Front Nutr 2021;8:807574. [PMID: 34988109 DOI: 10.3389/fnut.2021.807574] [Reference Citation Analysis]
4 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Reference Citation Analysis]
5 Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J Hepatol 2021:S0168-8278(21)01954-1. [PMID: 34339764 DOI: 10.1016/j.jhep.2021.07.025] [Reference Citation Analysis]
6 Huang PJ, Chiu CC, Hsiao MH, Yow JL, Tzang BS, Hsu TC. Potential of antiviral drug oseltamivir for the treatment of liver cancer. Int J Oncol 2021;59:109. [PMID: 34859259 DOI: 10.3892/ijo.2021.5289] [Reference Citation Analysis]
7 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Reference Citation Analysis]
8 Gao C, Shen J, Chen W, Yao L, Liang X, Zhu R, Chen Z. Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics. J Gastrointest Oncol 2021;12:1905-26. [PMID: 34532138 DOI: 10.21037/jgo-21-390] [Reference Citation Analysis]
9 Bell RF, Moreira VM, Kalso EA, Yli-Kauhaluoma J. Liquorice for pain? Ther Adv Psychopharmacol 2021;11:20451253211024873. [PMID: 34349979 DOI: 10.1177/20451253211024873] [Reference Citation Analysis]
10 Lupberger J, Baumert TF. Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges. J Clin Med 2021;11:208. [PMID: 35011949 DOI: 10.3390/jcm11010208] [Reference Citation Analysis]
11 Takaya H, Namisaki T, Takeda S, Kaji K, Ogawa H, Ishida K, Tsuji Y, Takagi H, Ozutsumi T, Fujinaga Y, Furukawa M, Kitagawa K, Nishimura N, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. J Clin Med 2021;10:4838. [PMID: 34768358 DOI: 10.3390/jcm10214838] [Reference Citation Analysis]